The Peptide Frontier: Why the Science Keeps Expanding

Few classes of medicine have changed clinical practice as quickly as GLP-1 medications. They are discussed almost entirely in terms of weight, yet the more interesting story is what they appear to do for the heart, the liver, the kidneys, inflammation, and possibly the brain. Alongside them sits a much broader and far less regulated world called "peptides." This review separates what is established from what is promising, and what is simply marketing.

What a peptide actually is

A peptide is a short chain of amino acids, the same building blocks as proteins, only smaller. The body uses thousands of them as signals: insulin, oxytocin, and GLP-1 itself are all peptides. "Peptide therapy" therefore describes a route of biology, not a single treatment, and it spans everything from rigorously tested prescription drugs to compounds sold online with no human data at all. That range is the single most important thing to understand before starting any of them.

How GLP-1 medications work

Glucagon-like peptide-1 is a hormone released by the gut after eating. It tells the pancreas to release insulin in proportion to blood sugar, slows stomach emptying, and signals satiety to the brain. Natural GLP-1 lasts only minutes; modern medications are engineered to last a week. Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on both GLP-1 and GIP receptors, a second gut hormone, which is part of why its weight effects are larger.

The benefits, system by system

Metabolism and body weight

In the STEP 1 trial, adults with obesity taking semaglutide 2.4 mg lost an average of about 15 percent of body weight over 68 weeks[1]. In SURMOUNT-1, tirzepatide at the highest dose produced an average loss of about 21 percent over 72 weeks[2]. These medications also improve fasting glucose, HbA1c, triglycerides, blood pressure, and liver fat.

Heart and blood vessels

The SELECT trial followed more than 17,000 adults with cardiovascular disease and overweight, without diabetes. Semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20 percent[3]. Notably, part of that benefit appeared early, before most of the weight was lost, which suggests effects beyond the scale.

Inflammation

Chronic, low-grade inflammation links obesity to heart disease, fatty liver, insulin resistance, and neurodegeneration. GLP-1 medications consistently lower C-reactive protein, a standard blood marker of inflammation, and GLP-1 receptors are present on immune cells, blood vessel walls, and microglia, the brain's resident immune cells[4]. Reduced inflammation is one of the leading explanations for why benefits appear across so many organ systems at once.

Liver, kidneys, and sleep

Semaglutide has shown benefit in metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and in slowing kidney disease progression in type 2 diabetes[5]. Tirzepatide is FDA approved for moderate to severe obstructive sleep apnea in adults with obesity, a meaningful development for anyone who cares about sleep and the brain[6].

The brain

This is the area our team watches most closely. GLP-1 receptors are found in the hippocampus and other regions involved in memory and reward. In laboratory models, GLP-1 activity reduces neuroinflammation, improves brain insulin signaling, and supports neuron survival. Large observational studies of people with diabetes have associated GLP-1 use with lower rates of dementia[7], and there is early research interest in addiction, mood, and recovery after brain injury.

Honesty matters here. The two large phase 3 EVOKE trials tested oral semaglutide in people with early Alzheimer's disease, and in late 2025 the sponsor reported that it did not slow disease progression[8]. That does not close the door on prevention, since treating metabolic and vascular risk years earlier is a different question, but GLP-1s are not a treatment for Alzheimer's disease, and anyone who tells you otherwise is ahead of the evidence.

The trade-offs no one should skip

Nausea, constipation, and reflux are common, especially during dose increases. Less common but serious risks include pancreatitis and gallbladder disease, and these drugs are not used in people with a personal or family history of medullary thyroid cancer or MEN2. Just as important for long-term health: a substantial share of weight lost can be lean tissue. Without adequate protein and resistance training, patients can lose muscle and bone that matter enormously for metabolism, falls, and healthy aging. Weight also tends to return when the medication stops. These are reasons for supervision, not reasons for fear.

FDA-approved peptides

These medications have completed formal clinical trials and FDA review for specific uses:

• Semaglutide (Ozempic, Wegovy, Rybelsus): type 2 diabetes, chronic weight management, and cardiovascular risk reduction.
• Tirzepatide (Mounjaro, Zepbound): type 2 diabetes, chronic weight management, and obstructive sleep apnea with obesity.
• Liraglutide, dulaglutide, exenatide (Victoza, Saxenda, Trulicity, Byetta): earlier GLP-1 medications.
• Tesamorelin (Egrifta): a growth hormone releasing hormone analog approved to reduce excess abdominal fat in HIV-associated lipodystrophy.
• Teriparatide and abaloparatide (Forteo, Tymlos): bone-building peptides for osteoporosis.
• Setmelanotide (Imcivree): obesity due to specific rare genetic conditions.
• Bremelanotide (Vyleesi): low sexual desire in premenopausal women.
• Long-established peptide drugs including insulin, oxytocin, octreotide, and leuprolide.

Peptides that are not FDA approved

Much of what is marketed online as "peptide therapy" falls here. Some have interesting animal data; very few have meaningful human trials.

• BPC-157: studied for tendon, ligament, and gut healing almost entirely in animals. The FDA has flagged it as a substance with potential safety concerns for compounding.
• TB-500 (a thymosin beta-4 fragment): marketed for recovery; limited human data, and prohibited in competitive sport.
• Ipamorelin and CJC-1295: growth hormone secretagogues popular in anti-aging circles, without approved indications or long-term safety data.
• Sermorelin: once FDA approved for pediatric growth hormone deficiency, then withdrawn by the manufacturer for commercial reasons. It is not currently approved for adult use.
• Selank, Semax, and other "nootropic" peptides: used in some countries, with small studies, but not approved in the United States.

"Not approved" does not automatically mean "dangerous," but it does mean the dose, purity, and long-term effects are not established. Products labeled "research use only" are not made for people, and competitive athletes should know that many of these compounds are banned by WADA and the NCAA.

What is coming next

• Retatrutide: a "triple agonist" acting on GLP-1, GIP, and glucagon receptors, which produced roughly 24 percent average weight loss in phase 2 and is now in phase 3 trials[9].
• Orforglipron: a once-daily pill that activates the GLP-1 receptor without being a peptide, potentially simplifying access.
• CagriSema: semaglutide combined with cagrilintide, an amylin analog that adds another satiety signal.
• Survodutide and maridebart cafraglutide: combination agents under study for obesity and fatty liver disease, the latter dosed monthly.
• Muscle-preserving strategies: drugs targeting myostatin and activin pathways are being tested alongside GLP-1s to protect lean mass.
• Neurological research: ongoing trials are exploring GLP-1 medications in Parkinson's disease, addiction, and brain injury recovery.

How we approach it at Raeven Health

We treat GLP-1 medications and peptides as tools inside a larger plan, never as the plan. That starts with a physician evaluation and laboratory testing, then attention to protein, strength training, sleep, and cognitive health so that the weight lost is fat, not function. We favor FDA-approved options where they fit, and we are candid when evidence for a compound is thin. Our physician-guided peptide and metabolic screening is available by telehealth to Florida residents; labs, medications, pharmacy dispensing, and shipping are billed separately.

This article is educational and is not medical advice. Whether any of these medications is appropriate for you depends on your history, goals, and a conversation with a physician who knows both.